Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, versus Investigator’s Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Project: Research

Project Details

StatusActive
Effective start/end date15/05/23 → 14/05/26

Keywords

  • Clinical Trials
  • MORAb-202
  • Farletuzumab Ecteribulin